Company intelligence / Profile preview

Aimmune Therapeutics

Brisbane, California, United States

Ownership: Private
Development stage: Commercial

Overview

Aimmune developed Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. Clinical trials demonstrated significant desensitization and protection against accidental exposure in children with peanut allergies. Additional candidates are in clinical development for egg and cow's milk allergies.[2][4][5]

Therapeutic areas: Immunology
Modalities: Oral immunotherapy (OIT)Characterized Oral Desensitization ImmunoTherapy (CODIT™)
Industry: Biotech

Drug pipeline

7 assets

peanut protein

6 more assets in the full pipeline.

Request access →

Partnerships

Nestlé Health Science US Holdings, Inc. (strategic collaboration and parent company)Regeneron Ireland Unlimited Company & Sanofi Biotechnology SAS – clinical collaboration to study Palforzia with dupilumab in peanut-allergic patients [5]

Beyond the preview

Go deeper on Aimmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aimmune Therapeutics.

Explore the full profile